CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel treatment for Parkinson's disease by using gold nanoparticles coated with beta-casein to deliver neurotrophic factors directly to the brain, bypassing the blood-brain barrier. The approach targets the reduction of alpha-synuclein aggregation and supports the survival of dopamine neu…
Parkinson’s disease (PD) is the second most common neurodegenerative disorder that is characterised by progressive loss of dopamine neurons and abnormal intra-neuronal accumulation of protein α-synuclein (αS).
None of the available treatments have shown ability to slow down the progression of the neurodegeneration.
One of the therapeutically potent approaches to combat PD is neurotrophic factor (NTF)-based therapies.
Delivery of NTFs to the brain shows a notable therapeutic potential due to the…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
